summit plc

MDA-supported Summit PLC announced it will continue testing it experimental drug in Duchenne MD patients, along with dietary modifications that may improve drug absorption

posted on December 22, 2014 - 11:22am

Compounds designed to alter genetic instructions for dystrophin, increase production of utrophin, or prevent scar tissue formation in muscle are moving through the development pipeline

posted on November 5, 2014 - 4:03pm
Drug development for Duchenne muscular dystrophy (DMD) is progressing on several fronts. Here are some updates as of early November 2014. PTC is moving forward with ataluren

SMT C1100, which increases levels of the protein utrophin, reached adequate blood levels in healthy volunteers; trials in Duchenne MD may be next

posted on October 10, 2012 - 4:15pm